X. Li

ORCID: 0000-0002-3474-2841
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Psoriasis: Treatment and Pathogenesis
  • Asthma and respiratory diseases
  • Urticaria and Related Conditions
  • Dermatology and Skin Diseases
  • Allergic Rhinitis and Sensitization
  • Immunotherapy and Immune Responses
  • Finite Group Theory Research
  • graph theory and CDMA systems
  • T-cell and B-cell Immunology
  • Cytokine Signaling Pathways and Interactions
  • Parkinson's Disease Mechanisms and Treatments
  • Immune Cell Function and Interaction
  • Neurological Disease Mechanisms and Treatments
  • Cerebrovascular and Carotid Artery Diseases
  • Autoimmune Bullous Skin Diseases
  • Retinal and Optic Conditions
  • Monoclonal and Polyclonal Antibodies Research
  • Cutaneous lymphoproliferative disorders research
  • Coding theory and cryptography

Xingtai People's Hospital
2024

Guizhou Normal University
2024

Hebei Medical University
2024

Qingdao University
2023

Affiliated Hospital of Qingdao University
2023

Rockefeller University
2016-2018

Aaron Diamond AIDS Research Center
2009

Parkinson’s disease (PD) is one of the common neurodegenerative diseases elderly. However, modern healthcare lacks apparatus to detect early signs disease, with only selected experts being able spot onset. Therefore, detection PD particularly important. Convolutional neural networks, a deep learning technique that can automatically extract image features, have been widely used in diagnosis medical images. Due complexity organization brain, we proposed multi-scale hybrid attention network...

10.1109/tim.2023.3315407 article EN IEEE Transactions on Instrumentation and Measurement 2023-09-18

10.1007/s10474-024-01470-7 article EN Acta Mathematica Academiae Scientiarum Hungaricae 2024-10-01

A novel assay to assess antigen-specific cytokine release from stimulated CD8(+) T cells derived the mucosal and peripheral blood compartments has been developed standardized using influenza virus matrix protein (MP) peptide, GILGFVFTL. This technology is based on capacity for human leucocyte antigen (HLA)-A2:Ig dimeric stimulate in a major histocompatibility complex (MHC) class I-restricted fashion without necessity presenting (APC). optimized utilizing 9-amino acid residue (9mer) optimal...

10.1111/j.1365-3083.2009.02317.x article EN Scandinavian Journal of Immunology 2009-08-26
Coming Soon ...